Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease

por Kumar, Anand, Kim, Emilie S, Kozan, Philip, Jacob, Vinita, Longman, Randy S, Scherl, Ellen J, Battat, Robert J, Lukin, Dana J
Publicado 2020